Sponsored by
News
Thousands of NHS patients to benefit from ‘take at home’ multiple sclerosis tablet in European first
Thousands of NHS patients in England with multiple sclerosis (MS) are set to benefit from a life-changing ‘take at home’ tablet, as the NHS becomes the first healthcare system in Europe to roll it out widely to patients with active disease. The tablet, cladribine, requires just 20 days of
treatment spread over four years, providing a convenient alternative to existing therapies that involve regular hospital infusions, frequent self- injections, and extensive monitoring. Patients planning a pregnancy can also safely conceive in years three and four of their treatment cycle because cladribine is administered in short courses over two years. Approved by the National Institute for Health
and Care Excellence (NICE) for patients with active relapsing-remitting MS, cladribine offers comparable clinical benefits to current treatments while significantly reducing hospital visits and clinical monitoring time. Previously approved only for patients with more
severe, highly active MS, the decision by NICE means cladribine is now available to a much wider group of patients. The rollout is expected to save thousands of clinical hours each year, freeing up capacity within the NHS by reducing the need for hospital appointments. Nearly eight in ten patients taking cladribine experienced no relapses, and MRI scans showed they developed 7.5 times fewer new brain lesions compared to patients given a placebo, in clinical trials lasting almost two years.
example of the NHS’s commitment to improving patient care through innovation.” Minister for Public Health, Ashley Dalton,
MS is a debilitating neurological condition affecting the brain and spinal cord, causing severe pain, fatigue, cognitive issues, and vision problems. More than 150,000 people in the UK currently live with the condition. Professor James Palmer, NHS Medical Director
for Specialised Commissioning, said: “The NHS is proud to be the first healthcare system in Europe to roll out this innovative ‘take at home’ tablet widely for patients with active multiple sclerosis. “Broadening access to cladribine means thousands more patients will benefit from managing their treatment at home rather than regularly attending hospital appointments – as well giving women with MS who want to get pregnant more flexibility to do so around their treatment. “This decision will also significantly free up
clinical time, helping clinicians see more patients and boosting NHS productivity. It’s another clear
said: “We know that patients with neurological conditions such as multiple sclerosis face immense challenges, so I am delighted that this decision means more patients will get access to a treatment that will greatly improve their quality of life. By expanding access to medicines that can be taken at home, we can shift care out of hospitals and into the community, giving patients more freedom and saving the NHS money.” Laura Thomas, Head of Policy at the MS Society, said: “It’s great news that NICE have recommended the disease modifying treatment (DMT) cladribine (Mavenclad) as an option for those with active relapsing remitting MS. Over 150,000 people live with MS in the UK, and many of them rely on DMTs like cladribine to help reduce MS relapses, so expanding patient choice is vital. “Cladribine is self-administered, so this decision could particularly benefit people who’d struggle to go into hospital regularly, like younger working- age adults. It will also benefit patients considering starting a family, as it’s safe to get pregnant six months after the final course of treatment – which is less restrictive than many other DMT options. We’re so glad that more people with MS will now be able to choose an effective treatment which suits their lifestyle.” It is estimated about 2,000 patients could be offered the treatment over the first three years.
April 2025 I
www.clinicalservicesjournal.com 13
bongkarn -
stock.adobe.com
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100
